Insider's sale of shares at a lower price may suggest belief in the stock's full valuation. However, this is a weak sign and doesn't definitively indicate their view on the stock's value. The lack of insider buying recently and history of sales make us cautious about the stock.
Columbus McKinnon's high P/E compared to the market appears justified due to expected earnings growth and potential EPS increase. This is anticipated to strongly support the share price, barring changes in circumstances.
BOFA •$Oscar Health (OSCR.US)$BofA analyst Kevin Fischbeck downgraded Oscar Health to Neutral from Buy with a price target of $6, down from $12. The analyst sees greater medical loss ratio uncertainty into 2023. The industry is going to have to manage through the expiration of the expanded Affordable Care Act subsidies, Medicaid redeterminations and the result shift within the risk pool making it more difficult to price, Fischb...
Columbus McKinnon Stock Forum
• $Oscar Health (OSCR.US)$ BofA analyst Kevin Fischbeck downgraded Oscar Health to Neutral from Buy with a price target of $6, down from $12. The analyst sees greater medical loss ratio uncertainty into 2023. The industry is going to have to manage through the expiration of the expanded Affordable Care Act subsidies, Medicaid redeterminations and the result shift within the risk pool making it more difficult to price, Fischb...
• $AmerisourceBergen (ABC.US)$ : Barclays Upgrades to Overweight from Equalweight - PT $182 (from $175)
• $Alignment Healthcare (ALHC.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $14 (from $18)
• $Cigna Group (CI.US)$ : BofA Securities Upgrades to Neutral from Underperform - PT $300 (from $265)
• $Canadian National Railway (CNI.US)$ : Evercore ISI Upgrades to Outperform from In Line
• $Youdao (DAO.US)$ : Citic Securities Upgrades to Buy from Neut...
No comment yet